Table 2.
Clinical trials evaluating immune checkpoint blockade in gliomas.
| NCT Number | Other IDs | Cancer Type | Study Results | Phases | Study Status | Treatment |
|---|---|---|---|---|---|---|
| NCT05235737 | PIRG | Newly Diagnosed Glioblastoma | N | PHASE 4 | R | Arm 1: Pembrolizumab as a neoadjuvant and adjuvant therapy to standard chemo-radiotherapy Arm 2: Pembrolizumab as a neoadjuvant therapy to standard chemo-radiotherapy Arm 3: Standard chemo-radiotherapy |
| NCT02617589 | CheckMate 498 | Newly Diagnosed Adult Subjects with Unmethylated MGMT GBM | Y | PHASE 3 | C | Arm 1: Nivolumab + Radiation Arm 2: Temozolomide + Radiation |
| NCT02017717 | CheckMate 143 | Recurrent Glioblastoma | Y | PHASE 3 | C | Arm 1: Nivolumab Arm 2: Bevacizumab |
| NCT02667587 | CheckMate548 | Newly Diagnosed Adult Subjects with MGMT-Methylated GBM | Y | PHASE 3 | C | Arm 1: Nivolumab + Radiation + Temozolomide Arm 2: Placebo + Radiation + Temozolomide |
| NCT06556563 | EF-41 | Newly Diagnosed Glioblastoma | N | PHASE 3 | NR | Arm 1: Optune® device + Temozolomide + Pembrolizumab Arm 2: Optune® device + Temozolomide + Placebo |
| NCT04396860 | Newly Diagnosed Adult Subjects with MGMT-Methylated GBM | Y | PHASE 2|PHASE 3 | NR | Arm 1: Radiation therapy + Temozolomide Arm 2: Radiation therapy + Ipilimumab + Nivolumab |
|
| NCT03430791 | Recurrent Glioblastoma | Y | PHASE 2 | T | Arm 1: Nivolumab monotherapy Arm 2: Nivolumab + Ipilimumab |
|
| NCT02794883 | Recurrent Malignant Glioma | Y | PHASE 2 | C | Arm 1: Tremelimumab Only Arm 2: MEDI4736 Only Arm 3: Tremelimumab + MEDI4736 |
|
| NCT03018288 | Newly diagnosed GBM without MGMT-Methylation | Y | PHASE 2 | T | Arm 1: Vaccine Arm 2: Placebo Arm 3: Ancillary Treatment |
|
| NCT02337686 | Recurrent Malignant Glioma | Y | PHASE 2 | NR | Pembrolizumab + Surgery | |
| NCT03661723 | Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma | Y | PHASE 2 | NR | Arm 1: COH A - Dose Level 0 (200 mg Pembrolizumab once every 3 Weeks + 2 Weeks of Radiation) Arm 2: COH B - Dose Level 0 (200 mg Pembrolizumab + 15 mg/kg Bevacizumab once every 3 Weeks + 2 Weeks of Radiation) |
|
| NCT02337491 | Recurrent Malignant Glioma | Y | PHASE 2 | C | Arm 1: Pembrolizumab + Bevacizumab Arm 2: Pembrolizumab |
|
| NCT03367715 | Newly Diagnosed, Unmethylated MGMT Glioblastoma | Y | PHASE 2 | C | Nivolumab + Ipilimumab + Short-course radiation therapy | |
| NCT04013672 | Glioblastoma at First Recurrence | Y | PHASE 2 | C | Arm 1: Have not received immunotherapy Arm 2: Have failed prior anti-PD-1 therapy |
|
| NCT05879120 | Recurrent Glioblastoma | N | PHASE 2 | NR | Arm 1: Neoadjuvant Pembrolizumab Arm 2: Exablate MRgFUS + neoadjuvant Pembrolizumab |
|
| NCT05463848 | Recurrent Glioblastoma | N | PHASE 2 | R | Cohort 1 (Safety Lead In): Pembrolizumab plus Olaparib and Temozolomide Cohort 2 (Surgical Cohort): Arm A - Pembrolizumab plus Olaparib and Temozolomide Cohort 3 (Surgical Cohort): Arm B - Pembrolizumab monotherapy |
|
| NCT05909618 | 14 | Glioblastoma and Melanoma with Brain Metastases | N | PHASE 2 | R | Cohort 1: Crizanlizumab + Nivolumab in Metastatic melanoma with brain metastases who failed immunotherapy Cohort 2: Crizanlizumab + Nivolumab in Patients with recurrent or progressing Glioblastoma following radiation and Temozolomide Cohort 3: Crizanlizumab + Nivolumab in Patients with newly diagnosed Glioblastoma |
| NCT03014804 | Recurrent Glioblastoma | N | PHASE 2 | W | Arm 1: DCVax-L Arm 2: DCVax-L + Nivolumab |
|
| NCT04225039 | Recurrent Glioblastoma | Y | PHASE 2 | NR | Arm 1: GITR + INCMGA00012 (anti-PD-1) + SRS Arm 2: GITR + INCMGA00012 (anti-PD-1) + SRS + Surgery Arm 3: GITR + INCMGA00012 (anti-PD-1) + Surgery |
|
| NCT06328036 | Recurrent Glioblastoma | N | PHASE 2 | NR | Arm 1: Neoadjuvant Atezolizumab + Tiragolumab Arm 2: Neoadjuvant Tiragolumab Arm 3: Neoadjuvant Atezolizumab Arm 4: No neoadjuvant drug |
|
| NCT04817254 | Newly Diagnosed Glioblastoma or Gliosarcoma | N | PHASE 2 | R | Arm 1: Nivolumab + Ipilimumab 1mg/kg + Temozolomide Arm 2: Nivolumab + Ipilimumab 3 mg/kg + Temozolomide |
|
| NCT03452579 | Recurrent Glioblastoma | N | PHASE 2 | NR | Arm 1: Nivolumab + Standard dose Bevacizumab 10 mg/kg Arm 2: Nivolumab + Low dose Bevacizumab 3 mg/kg |
|
| NCT06325683 | Recurrent Glioblastoma | N | PHASE 2 | NR | Arm 1: Nivolumab + Relatlimab Arm 2: Lomustine |
|
| NCT06558214 | OPTIMUS PRIME | Recurrent Glioblastoma | N | PHASE 2 | NR | Arm 1: Optune GIO® pre-MLA; MLA; followed by Optune GIO® + Pembrolizumab post MLA Arm 2: Optune GIO® + Pembrolizumab pre-MLA; MLA; followed by Optune GIO® + Pembrolizumab post MLA |
| NCT04118036 | Recurrent Glioblastoma | N | PHASE 2 | W | Arm 1: Pembrolizumab + Abemaciclib + Surgery Arm 2: Pembrolizumab + Abemaciclib + non-surgery |
|
| NCT03797326 | Previously Treated Subjects with Selected Solid Tumors (LEAP-005) | N | PHASE 2 | NR | Arm 1: Pembrolizumab + Lenvatinib Arm 2: Lenvatinib monotherapy |
|
| NCT03197506 | Newly Diagnosed Glioblastoma | N | PHASE 2 | S | Arm 1: Pembrolizumab + Surgery + Temozolomide + Radiation Arm 2: Pembrolizumab + Temozolomide + Radiation therapy |
|
| NCT04195139 | NUTMEG | Newly Diagnosed Elderly Patients with Glioblastoma (NUTMEG) | N | PHASE 2 | NR | Arm 1: Radiotherapy + Nivolumab and Temozolomide Arm 2: Radiotherapy + Temozolomide |
| NCT03743662 | Recurrent MGMT Methylated Glioblastoma | N | PHASE 2 | NR | Arm 1: Re-irradiation + Bevacizumab + Nivolumab + Recurrent Glioblastoma + No Surgery Arm 2: Re-irradiation + Bevacizumab + Nivolumab + Recurrent Glioblastoma + Surgery |
|
| NCT04729959 | Recurrent Glioblastoma | N | PHASE 2 | R | Arm 1: Tocilizumab + Atezolizumab + FSRadiation Arm 2: Tocilizumab + Atezolizumab + FSRadiation + surgery Arm 3: Tocilizumab + Atezolizumab + FSRadiation + surgery |
|
| NCT03890952 | Recurrent Glioblastoma | N | PHASE 2 | NR | Arm B: Nivolumab and Bevacizumab in patients not undergoing salvage surgery Arm A: Nivolumab and Bevacizumab in patients undergoing salvage surgery |
|
| NCT02798406 | CAPTIVE | Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192) | N | PHASE 2 | C | DNX-2401 + Pembrolizumab |
| NCT05465954 | Recurrent Glioblastoma | N | PHASE 2 | R | Efineptakin alfa + Pembrolizumab before and after surgery | |
| NCT03347617 | Glioblastoma | N | PHASE 2 | NR | Ferumoxytol MRI + Pembrolizumab | |
| NCT05074992 | NeAT Glio | Newly Diagnosed Glioblastoma | N | PHASE 2 | T | Ipilimumab |
| NCT04479241 | Recurrent Glioblastoma | N | PHASE 2 | NR | Lerapolturev + Pembrolizumab | |
| NCT02550249 | Neo-Nivolumab | Glioblastoma | N | PHASE 2 | C | Nivolumab |
| NCT04145115 | Somatically Hypermutated Recurrent WHO Grade 4 Glioma | N | PHASE 2 | S | Nivolumab + Ipilimumab | |
| NCT03718767 | IDH-Mutant Gliomas with and without Hypermutator Phenotype | N | PHASE 2 | R | Nivolumab in IDH-mutant gliomas patients with and without HMP in response | |
| NCT03899857 | PERGOLA | Newly Diagnosed Glioblastoma | N | PHASE 2 | NR | Pembrolizumab + Temozolomide-based chemoradiation |
| NCT06069726 | MOAB | Recurrent Glioblastoma | N | PHASE 2 | R | Pre-Surgery Atezolizumab |
| NCT03405792 | 2-THE-TOP | Newly Diagnosed Glioblastoma | Y | PHASE 2 | NR | Arm 1: Optune system combined with Temozolomide + Pembrolizumab Arm 2: Historical control |
T = terminated; C = completed; NR = not recruiting; R = recruiting; W = withdrawn; S = suspended; Y = yes; N = no.